Patents by Inventor Luke O'Neill
Luke O'Neill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11858922Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.Type: GrantFiled: February 16, 2017Date of Patent: January 2, 2024Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray Macleod, David John Miller
-
Patent number: 11845715Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: GrantFiled: August 18, 2021Date of Patent: December 19, 2023Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Patent number: 11840543Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.Type: GrantFiled: May 24, 2017Date of Patent: December 12, 2023Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray MacLeod, David John Miller
-
Publication number: 20220112159Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: ApplicationFiled: August 18, 2021Publication date: April 14, 2022Inventors: Luke O'NEILL, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Patent number: 11278593Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.Type: GrantFiled: May 2, 2019Date of Patent: March 22, 2022Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Matthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'Neill
-
Patent number: 11130731Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: GrantFiled: August 7, 2019Date of Patent: September 28, 2021Assignees: The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The University Of QueenslandInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Publication number: 20200299284Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.Type: ApplicationFiled: February 16, 2017Publication date: September 24, 2020Inventors: Luke O'NEILL, Rebecca COLL, Matthew COOPER, Avril ROBERTSON, Kate SCHRODER, Angus Murray MACLEOD, David John MILLER
-
Publication number: 20200207780Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.Type: ApplicationFiled: May 24, 2017Publication date: July 2, 2020Inventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray MacLeod, David John Miller
-
Patent number: 10538487Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: GrantFiled: February 16, 2016Date of Patent: January 21, 2020Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Publication number: 20190359564Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: ApplicationFiled: August 7, 2019Publication date: November 28, 2019Applicants: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLInventors: Luke O'NEILL, Rebecca COLL, Matthew COOPER, Avril ROBERTSON, Kate SCHRODER
-
Publication number: 20190314454Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.Type: ApplicationFiled: May 2, 2019Publication date: October 17, 2019Inventors: Matthew CAMPBELL, Peter HUMPHRIES, Marian HUMPHRIES, Anna-Sophia KIANG, Sarah DOYLE, Luke O'NEILL
-
Publication number: 20180044287Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Inventors: Luke O'NEILL, Rebecca COLL, Matthew COOPER, Avril ROBERTSON, Kate SCHRODER
-
Patent number: 9234046Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.Type: GrantFiled: June 19, 2012Date of Patent: January 12, 2016Assignee: OPSONA Therapeutics LtdInventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
-
Patent number: 9038230Abstract: A cleaning device for a safety razor having single or multiple parallel blades is disclosed. A hollow connector is affixed to a water tap of a bathroom sink allowing water to flow therethrough into a body depending from the connector, rotating a brush held in the body and exiting through a slot in the body. The shaving head of the razor is positioned with the slot such that the blades within the head are embedded within the bristles of the brush. As the brush rotates, its bristles remove shaving debris from between the blades and immediate surrounds. After use, the device can easily be disassembled to facilitate cleaning of all components thereof.Type: GrantFiled: September 25, 2012Date of Patent: May 26, 2015Inventor: Luke O'Neill
-
Publication number: 20140304928Abstract: A cleaning device for a safety razor having single or multiple parallel blades is disclosed. A hollow connector is affixed to a water tap of a bathroom sink allowing water to flow therethrough into a body depending from the connector, rotating a brush held in the body and exiting through a slot in the body. The shaving head of the razor is positioned with the slot such that the blades within the head are embedded within the bristles of the brush. As the brush rotates, its bristles remove shaving debris from between the blades and immediate surrounds. After use, the device can easily be disassembled to facilitate cleaning of all components thereof.Type: ApplicationFiled: September 25, 2012Publication date: October 16, 2014Inventor: Luke O'Neill
-
Publication number: 20140234252Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.Type: ApplicationFiled: October 1, 2012Publication date: August 21, 2014Inventors: Matthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'neill
-
Patent number: 8734788Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.Type: GrantFiled: August 4, 2008Date of Patent: May 27, 2014Assignee: OPSONA Therapeutics LtdInventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
-
Patent number: 8580255Abstract: The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.Type: GrantFiled: June 27, 2008Date of Patent: November 12, 2013Assignee: OPSONA Therapeutics LtdInventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
-
Patent number: 8414887Abstract: The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression Toll-like Receptor 4 mediated activation of the immune system. The invention further provides screening assays to identify compounds which have utility in the foregoing compositions and methods.Type: GrantFiled: October 18, 2007Date of Patent: April 9, 2013Assignee: Opsona Therapeutics LimitedInventors: Luke O'Neill, Susan Carpenter, Aisling Dunne
-
Publication number: 20120258103Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.Type: ApplicationFiled: June 19, 2012Publication date: October 11, 2012Applicant: OPSONA Therapeutics LtdInventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher